Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Thursday that it has received a EUR2.4m grant from the German Federal Ministry of Education and Research (BMBF) to support its Phase 2 clinical trial for NOX-A12, a potential treatment for glioblastoma.
This non-dilutive funding, combined with other grants totalling approximately EUR5m, will support the randomised controlled study evaluating NOX-A12 in combination with bevacizumab.
The Phase 2 trial, approved by the US Food and Drug Administration (FDA) and the German regulator, aims to optimise the dosing regimen and assess the efficacy of the combination therapy.
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Clarivate adds Pathway Maps to OFF-X, boosting drug safety intelligence
GSK to acquire efimosfermin in USD2bn deal to expand hepatology pipeline
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
Hoth Therapeutics reports positive HT-KIT preclinical results
Solve M.E. announces Dr Akiko Iwasaki as first recipient of inaugural ME/CFS Catalyst Award
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
RemeGen reports positive phase 3 results for disitamab vedotin in advanced urothelial carcinoma
Lilly and Purdue University expand collaboration, announce investment
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial